Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc is a commercial-stage biotech company built on its ImmTAX bispecific TCR platform, aiming to treat cancer, infectious and autoimmune diseases. Its first product, KIMMTRAK, is approved for metastatic uveal melanoma in 39 countries and launched commercially in 30.
In 2025, revenue from sale of therapies reached $400.0 million, up from $310.0 million in 2024, driven mainly by the United States at $257.0 million, with Europe contributing $131.4 million and international markets $11.6 million. As of January 31, 2026, Immunocore had 50,695,078 ordinary shares outstanding.
The company is running multiple late-stage oncology trials, including three Phase 3 studies for KIMMTRAK and PRAME‑targeted brenetafusp, and advancing infectious disease candidates for HIV and hepatitis B as well as new autoimmune programs IMC‑S118AI and IMC‑U120AI. Management highlights ongoing losses, funding needs, competitive pressures, regulatory risk and IP challenges as key risk factors.
Coy Travis Alan reported acquisition or exercise transactions in this Form 4 filing.
Immunocore Holdings plc reported that Chief Financial Officer Travis Alan Coy received new equity awards. On February 17, 2026, he was granted 33,353 Restricted Share Units, each representing a contingent right to receive one Ordinary Share, which vest in four equal annual installments starting February 17, 2027, subject to continuous service.
He was also granted an option over 95,637 shares, with 25% vesting on February 17, 2027 and 6.25% vesting in quarterly installments thereafter, also subject to continuous service. Ordinary Shares may be represented by American Depositary Shares, with each ADS equal to one Ordinary Share.
Immunocore Holdings plc chief executive officer Bahija Jallal reported several equity transactions. She sold 11,474 Ordinary Shares in an open-market transaction at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to pay income taxes triggered by vesting restricted share units.
On a separate date, she acquired 23,817 Ordinary Shares at no cost through the exercise of Restricted Share Units, with each RSU converting into one Ordinary Share. She was also granted 88,573 new RSUs and 395,066 employee share options, each award vesting in scheduled installments starting in February 2026 or February 2027, contingent on continued service.
Immunocore Holdings plc executive John Goll reported both equity awards and a small tax-related share sale. As SVP, Finance & CAO, he sold 698 Ordinary Shares on February 18, 2026 in an open-market transaction at a weighted average price of $32.35 per share under a sell-to-cover arrangement to satisfy income tax liabilities from vesting restricted share units (RSUs).
On February 17, 2026, he acquired 1,351 Ordinary Shares through the exercise of RSUs, and received grants of 7,411 additional RSUs and 21,252 employee share options. The new RSUs and options vest in equal annual and quarterly installments beginning in February 2027, subject to his continuous service.
Immunocore Holdings plc reported insider transactions by Chief HR Officer Tina Amber St Leger. On February 18, 2026, she completed an open-market sale of 1,000 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
On February 17, 2026, 2,119 Restricted Share Units were exercised and converted into 2,119 Ordinary Shares at no cost, with each RSU representing one Ordinary Share. After these transactions, she directly held 1,119 Ordinary Shares and 6,357 RSUs.
Immunocore Holdings plc’s Head of R&D, David M. Berman, reported RSU vesting, share issuance and a related tax sale. On February 17, 2026, he exercised 11,824 Restricted Share Units, receiving the same number of Ordinary Shares at a $0.00 exercise price.
On February 18, 2026, he conducted an open-market sale of 5,965 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from RSU vesting. After these transactions, he directly held 5,859 Ordinary Shares and 35,473 RSUs. Each RSU and each American Depositary Share represents one Ordinary Share.
Immunocore plc reported planned insider stock sales via Form 144. The filing lists multiple proposed disposals of American Depositary Receipts (ADRs) by David Berman on dates in November and December 2025, with individual ADR quantities and aggregated dollar values shown for each sale date.
T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to a Schedule 13G/A reporting a sizeable passive stake in Immunocore Holdings plc – ADR. As of 12/31/2025, it beneficially owned 5,961,227 ADRs, representing 11.8% of the outstanding class.
The firm reports sole voting and sole dispositive power over all 5,961,227 ADRs, with no shared voting or dispositive power. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunocore.